Management of ATherothrombosis with Clopidogrel in High-risk patients with recent TIA or ischemic stroke "MATCH"

Completed

Phase N/A Results

Trial Description

To determine whether the combination of clopidogrel plus acetylsalicylic acid (ASA) is superior to clopidogrel alone in preventing ischemic events in patients with a recent TIA or ischemic stroke.

Interventions

Trial Design

International, randomized, double-blind, prospective, parallel-group trial with a planned enrollment of 7600 patients.

Patient Involvement

Patients will be randomized to receive ASA 75 mg or placebo once per day. Both groups will receive clopidogrel 75 mg once per day. Patients will be treated for 18 months with follow-up visits at 1 month, 3 months, 6 months, 12 months and 18 months, in addition to regular phone calls between visits.

Outcomes

Type Measure Time Frame Safety Issue
Primary Composite incidence of ischemic stroke, MI, vascular death, and rehospitalization for an acute ischemic event.
Secondary Any death, any stroke, modified Rankin scale (MRS) assessment, life-threatening bleeding events, all bleeding events, other adverse events.

Sponsors

Sanofi-Synthelabo Recherche, France